Gupta Suneel Insider Trades

Insider Trading History

Track insider trading activity for Gupta Suneel. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Protagonist Therapeutics
Protagonist Therapeutics PTGX
Chief Development Officer
Holding Value $31.8M 266,983 shares
Last Trade
Nov 26, 2024 Sale (Open Market)Shares sold on the open market or in a private sale.
$873k 19,191 shares
$45.50
$118.96
Protagonist Therapeutics
Protagonist Therapeutics PTGX
Chief Development Officer
Holding Value $34M 286,174 shares
Last Trade
Nov 26, 2024 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$1.37M 30,450 shares
$44.83
$118.96
Protagonist Therapeutics
Protagonist Therapeutics PTGX
Chief Development Officer
Holding Value $30.5M 256,174 shares
Last Trade
Nov 25, 2024 Sale (Open Market)Shares sold on the open market or in a private sale.
$4.76M 103,437 shares
$46.04
$118.96
Protagonist Therapeutics
Protagonist Therapeutics PTGX
Chief Development Officer
Holding Value $42.8M 359,611 shares
Last Trade
Nov 25, 2024 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$5.92M 130,000 shares
$45.53
$118.96
Protagonist Therapeutics
Protagonist Therapeutics PTGX
Chief Development Officer
Holding Value $21.8M 183,285 shares
Last Trade
Feb 26, 2024 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$126k 4,282 shares
$29.53
$118.96
Protagonist Therapeutics
Protagonist Therapeutics PTGX
Chief Development Officer
Holding Value $5.35M 45,000 shares
Last Trade
Jan 09, 2024 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$127k 5,000 shares
$25.39
$118.96
Protagonist Therapeutics
Protagonist Therapeutics PTGX
Chief Development Officer
Holding Value $22.9M 192,567 shares
Last Trade
Jan 09, 2024 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$127k 5,000 shares
$25.39
$118.96
Protagonist Therapeutics
Protagonist Therapeutics PTGX
Chief Development Officer
Holding Value $22.3M 187,567 shares
Last Trade
Jan 09, 2024 Sale (Open Market)Shares sold on the open market or in a private sale.
$125k 5,000 shares
$25.00
$118.96
Protagonist Therapeutics
Protagonist Therapeutics PTGX
Chief Development Officer
Holding Value $22.3M 187,567 shares
Last Trade
Jan 02, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.67M 71,500 shares
$23.42
$118.96
Protagonist Therapeutics
Protagonist Therapeutics PTGX
Chief Development Officer
Holding Value $20M 168,317 shares
Last Trade
Oct 19, 2023 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$288k 20,000 shares
$14.41
$118.96
Protagonist Therapeutics
Protagonist Therapeutics PTGX
Chief Development Officer
Holding Value $5.95M 50,000 shares
Last Trade
Oct 19, 2023 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$288k 20,000 shares
$14.41
$118.96
Protagonist Therapeutics
Protagonist Therapeutics PTGX
Chief Development Officer
Holding Value $18.1M 152,187 shares
Last Trade
May 31, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$313k 12,000 shares
$26.07
$118.96
Protagonist Therapeutics
Protagonist Therapeutics PTGX
Chief Development Officer
Holding Value $17.6M 148,037 shares
Last Trade
May 31, 2023 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$108k 4,150 shares
$26.07
$118.96
Protagonist Therapeutics
Protagonist Therapeutics PTGX
Chief Development Officer
Holding Value $8.33M 70,000 shares
Last Trade
Apr 26, 2022 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$376k 40,000 shares
$9.41
$118.96
Protagonist Therapeutics
Protagonist Therapeutics PTGX
Chief Development Officer
Holding Value $9.16M 77,007 shares
Last Trade
Feb 28, 2022 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$15.8k 649 shares
$24.28
$118.96
Protagonist Therapeutics
Protagonist Therapeutics PTGX
Chief Development Officer
Holding Value $9.24M 77,656 shares
Last Trade
Feb 15, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$2.15M 75,000 shares
$28.73
$118.96
Protagonist Therapeutics
Protagonist Therapeutics PTGX
Chief Development Officer
Holding Value $9.52M 80,000 shares
Last Trade
Feb 26, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.89M 80,000 shares
$23.57
$118.96
Protagonist Therapeutics
Protagonist Therapeutics PTGX
Chief Development Officer
Holding Value $10.1M 85,000 shares
Last Trade
Feb 28, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$663k 85,000 shares
$7.80
$118.96
Protagonist Therapeutics
Protagonist Therapeutics PTGX
EVP Clinical Operations
Holding Value $5.89M 49,500 shares
Last Trade
Dec 03, 2019 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$154k 30,000 shares
$5.13
$118.96
Protagonist Therapeutics
Protagonist Therapeutics PTGX
EVP Clinical Operations
Holding Value $5.35M 45,000 shares
Last Trade
Feb 28, 2019 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$361k 45,000 shares
$8.02
$118.96

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up